CAMBRIDGE, MA / ACCESS Newswire / August 1, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the UK Court of Appeal ...

PFE posts strong Q2 results with earnings up 30% and revenues up 10% year over year, fueled by rising oncology sales and cost ...

Pfizer raised its full-year profit forecast on Tuesday while reporting second-quarter results that topped Wall Street ...

Pfizer raised its full-year profit forecast on Tuesday after topping Wall Street expectations for second-quarter results as ...

Pharmaceutical major recorded a revenue jump to $14.65 billion, exceeding the market expectations. The company also raised ...

The trade war between China and the US is entering the next round and reaching a new peak. The Middle Kingdom is restricting ...

Now, it’s worth noting Stock Advisor's total average return is 1,019% — a market-crushing outperformance compared to 178% for the S&P 500. Don’t miss out on the latest top 10 list, available when you ...

The researchers followed participants from October 2024 to January 2025. Median age was 76 years, and 54.2% were women. By ...

Second quarter earnings season is in full swing, and the results have been largely positive so far, with more positive ...

The company posted strong second-quarter results and reaffirmed its guidance for 2025. Enbridge posted EBITDA of C$4.6 ...

The Mpox outbreak has renewed interest in Kenya from various foreign vaccine suppliers. One of the few WHO-approved Mpox ...

Pfizer (PFE) increased its 2025 profit outlook by 10 cents a share to a range of $2.90 to $3.10 a share, citing continued cost cuts, a lower tax rate and "confidence" that strength seen in the first ...